Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced that it has received marketing approval for its enoxaparin in Niger. This development marks an important step for Changshan Bio as it expands the international reach of its pharmaceutical products.
Changshan Bio’s enoxaparin is a low molecular weight heparin used for the prevention of venous thromboembolic diseases, particularly focusing on thrombosis associated with orthopedic or general surgery. The drug is also indicated for the treatment of existing deep vein thrombosis, whether complicated by pulmonary embolism or presenting with mild clinical symptoms that do not require surgical intervention or thrombolytic therapy. Additionally, enoxaparin is used in combination with aspirin for the treatment of unstable angina and non-Q-wave myocardial infarction. Furthermore, it plays a crucial role in extracorporeal circulation for hemodialysis by preventing thrombus formation.
The marketing approval in Niger highlights Changshan Bio’s commitment to improving global health by providing access to essential medications for cardiovascular and thromboembolic diseases.- Flcube.com
